ACOR News and Press, Acorda Therapeutics Inc. From 03/05/23

2023-03-05 14:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Acorda Therapeutics ( NASDAQ: ACOR ) said the Nasdaq had granted extension request until June 20 to regain compliance with its minimum $1 bid price per share requirement. Press Release For further details see: Acorda Therapeutics receives Nasdaq extension to meet mi...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Nasdaq Hearings Panel has granted the Company’s extension request until June 20, 2023 to regain compliance with the Nasdaq's minimum $1 bid price per share requirement. “We are pleased Nasdaq has granted us this e...

Presentation on Thursday, February 2, 2023 at 3:00 p.m. ET Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will make a virtual presentation at the Sequire Biotechnology Conference on Thursday, February 2 at ...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

Acorda Therapeutics ( NASDAQ: ACOR ) on Thursday said it had entered into a new long-term global supply agreement with Catalent ( NYSE: CTLT ) for its inhalation powder Inbrija. As per the agreement, CTLT will continue to make Inbrija through 2030. Acorda's ( ACOR ) In...

Significant reduction in minimum purchase requirements 2026 manufacturing capacity expansion expected to result in further reductions in cost of goods Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that on December 31, 2022 it entered into a new long-term global supp...

Due to errors identified in the company’s year-end budgeting process, neurology-focused biotech Acorda Therapeutics ( NASDAQ: ACOR ) revised its outlook on Thursday, indicating positive adj. EBITDA of $5.6M - $5.8M for 2022. With its Nov. 01 financial results for Q3 2022, Acorda ( ...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has revised and updated the long-term financial guidance most recently included in its November 1, 2022 press release announcing its financial results for the third quarter of 2022. The revised guidance corrects certain errors ident...